Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Glioblastoma
MGMT
Obesity
Temozolomide
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
01
02
2022
accepted:
23
05
2022
pubmed:
16
6
2022
medline:
29
7
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy. The impact of obesity (BMI ≥ 30 kg/m Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7-30.8) vs. 43.2 (32.5-54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8-18.9) vs 17.6 (14.7-20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53-4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm. Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.
Identifiants
pubmed: 35704157
doi: 10.1007/s11060-022-04046-z
pii: 10.1007/s11060-022-04046-z
pmc: PMC9325931
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
DNA Modification Methylases
EC 2.1.1.-
DNA Repair Enzymes
EC 6.5.1.-
Temozolomide
YF1K15M17Y
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-101Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KG1005
Informations de copyright
© 2022. The Author(s).
Références
Gerontology. 2014;60(6):475-82
pubmed: 24993678
Neuro Oncol. 2022 May 02;:
pubmed: 35511454
J Neurooncol. 2013 Aug;114(1):79-84
pubmed: 23666204
Cancer Res. 2019 Jan 1;79(1):99-113
pubmed: 30361254
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Eur J Cancer. 2021 Mar;145:171-178
pubmed: 33486440
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
J Am Med Dir Assoc. 2014 May;15(5):342-8
pubmed: 24534518
Clin Nutr. 2019 Dec;38(6):2806-2812
pubmed: 30583963
Cancer Causes Control. 2021 Apr;32(4):327-336
pubmed: 33447892
Front Oncol. 2021 Mar 29;11:633210
pubmed: 33854970
PLoS One. 2008 Jun 04;3(6):e2329
pubmed: 18523653
Clin Neurol Neurosurg. 2018 Jul;170:165-169
pubmed: 29803727
Free Radic Biol Med. 2005 Mar 15;38(6):755-62
pubmed: 15721986
Neuro Oncol. 2019 Dec 17;21(12):1587-1594
pubmed: 31369680
Int J Obes (Lond). 2014 Aug;38(8):1110-4
pubmed: 24173404
Int J Cancer. 2021 Apr 1;148(7):1695-1707
pubmed: 33113214
J Clin Oncol. 2016 May 10;34(14):1611-9
pubmed: 26976423
Cancer Res. 2018 Apr 15;78(8):1906-1912
pubmed: 29654153
Endocrinology. 2007 Jan;148(1):293-9
pubmed: 17023529
Eur J Cancer. 2008 Sep;44(14):2050-7
pubmed: 18667300
Cancer Causes Control. 2010 Dec;21(12):2195-201
pubmed: 20838873
J Neurooncol. 2020 Sep;149(3):421-427
pubmed: 32989681
Future Oncol. 2021 Nov;17(32):4405-4413
pubmed: 34409854
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):204-209
pubmed: 30102196
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Diabetes Metab Disord. 2018 Apr 11;17(1):45-51
pubmed: 30288385
J Neurooncol. 2012 Jan;106(2):383-9
pubmed: 21833800
J Clin Oncol. 2009 Mar 1;27(7):1082-6
pubmed: 19139429
Neuro Oncol. 2018 Mar 27;20(4):576-577
pubmed: 29474647
Integr Cancer Ther. 2021 Jan-Dec;20:1534735421991233
pubmed: 33543653
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
DNA Repair (Amst). 2019 Jun;78:128-141
pubmed: 31039537
Neuro Oncol. 2020 Dec 18;22(12):1742-1756
pubmed: 32897363
J Clin Invest. 2021 Jul 13;:
pubmed: 34255747